Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311331041> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4311331041 endingPage "106002802211404" @default.
- W4311331041 startingPage "106002802211404" @default.
- W4311331041 abstract "To describe the safety, efficacy, and potential role in therapy of ponesimod, which was recently approved by the Food and Drug Administration (FDA) as a therapeutic option for the treatment of multiple sclerosis (MS).A PubMed literature search using the following terms: ponesimod and MS (January 1, 2012-October 31, 2022). FDA product labeling was also reviewed for pertinent data sources.All relevant English-language articles examining efficacy and/or safety of ponesimod were considered for inclusion.Ponesimod is an orally administered second-generation sphingosine 1-phospate (S1-P) receptor modulator classified as a disease modifying treatment (DMT) for MS. Clinical studies have shown that ponesimod prevents relapse in patients with relapsing-remitting MS (RRMS) and has superior efficacy compared with teriflunomide. Nasopharyngitis, upper respiratory tract infections, headache, high blood pressure, and liver dysfunction were some of the common adverse effects associated with ponesimod. Dyspnea, bradyarrhythmias, atrioventricular conduction delays, and macular edema were some of the rare but serious adverse effects associated with ponesimod.Some advantages of ponesimod over other S1-P receptor modulators approved for RRMS include selectivity for the S1-P1 receptor and short half-life, which allows for quick reversal of immunosuppressive effects. However, data from long-term efficacy and safety studies and more direct comparison studies with other DMTs are required.Currently available data suggest that ponesimod is a useful addition to other high-efficacy DMTs available to treat patients with MS." @default.
- W4311331041 created "2022-12-25" @default.
- W4311331041 creator A5068813541 @default.
- W4311331041 creator A5073093025 @default.
- W4311331041 creator A5083913282 @default.
- W4311331041 date "2022-12-13" @default.
- W4311331041 modified "2023-09-29" @default.
- W4311331041 title "Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis" @default.
- W4311331041 cites W1604550075 @default.
- W4311331041 cites W1723112598 @default.
- W4311331041 cites W1994878371 @default.
- W4311331041 cites W2002360349 @default.
- W4311331041 cites W2022390306 @default.
- W4311331041 cites W2095707498 @default.
- W4311331041 cites W2160992314 @default.
- W4311331041 cites W2508930552 @default.
- W4311331041 cites W2911658427 @default.
- W4311331041 cites W3012517977 @default.
- W4311331041 cites W3042308502 @default.
- W4311331041 cites W3065454939 @default.
- W4311331041 cites W3147565333 @default.
- W4311331041 cites W3149798718 @default.
- W4311331041 cites W3155041105 @default.
- W4311331041 cites W4211090999 @default.
- W4311331041 cites W4226013340 @default.
- W4311331041 cites W4281753257 @default.
- W4311331041 cites W4307582098 @default.
- W4311331041 cites W4376848271 @default.
- W4311331041 doi "https://doi.org/10.1177/10600280221140480" @default.
- W4311331041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36514282" @default.
- W4311331041 hasPublicationYear "2022" @default.
- W4311331041 type Work @default.
- W4311331041 citedByCount "3" @default.
- W4311331041 countsByYear W43113310412023 @default.
- W4311331041 crossrefType "journal-article" @default.
- W4311331041 hasAuthorship W4311331041A5068813541 @default.
- W4311331041 hasAuthorship W4311331041A5073093025 @default.
- W4311331041 hasAuthorship W4311331041A5083913282 @default.
- W4311331041 hasConcept C126322002 @default.
- W4311331041 hasConcept C197934379 @default.
- W4311331041 hasConcept C71924100 @default.
- W4311331041 hasConcept C98274493 @default.
- W4311331041 hasConceptScore W4311331041C126322002 @default.
- W4311331041 hasConceptScore W4311331041C197934379 @default.
- W4311331041 hasConceptScore W4311331041C71924100 @default.
- W4311331041 hasConceptScore W4311331041C98274493 @default.
- W4311331041 hasFunder F4320318311 @default.
- W4311331041 hasLocation W43113310411 @default.
- W4311331041 hasLocation W43113310412 @default.
- W4311331041 hasOpenAccess W4311331041 @default.
- W4311331041 hasPrimaryLocation W43113310411 @default.
- W4311331041 hasRelatedWork W1966939585 @default.
- W4311331041 hasRelatedWork W1998719043 @default.
- W4311331041 hasRelatedWork W2016348011 @default.
- W4311331041 hasRelatedWork W2374781999 @default.
- W4311331041 hasRelatedWork W2527805684 @default.
- W4311331041 hasRelatedWork W2804867142 @default.
- W4311331041 hasRelatedWork W2885964272 @default.
- W4311331041 hasRelatedWork W2968926940 @default.
- W4311331041 hasRelatedWork W2977219671 @default.
- W4311331041 hasRelatedWork W4236673861 @default.
- W4311331041 isParatext "false" @default.
- W4311331041 isRetracted "false" @default.
- W4311331041 workType "article" @default.